Skip to main content
. 2024 Mar 12;14(3):e072300. doi: 10.1136/bmjopen-2023-072300

Figure 3.

Figure 3

Cumulative incidence of drug discontinuation by stop reason and by type of treatment, Swiss Clinical Quality Management registry, 2017–2020. This figure represents the unadjusted cumulative incidence of drug discontinuation, by group and by reason of discontinuation. BARI, baricitinib; OMA, other modes of action bDMARDs; TNFi, tumour necrosis factor inhibitors.